NCT06520111 CRISAL Study:Cancer Risk In Secreting Adrenal Lesions
| NCT ID | NCT06520111 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Roma La Sapienza |
| Condition | Adrenal Tumor |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-08-27 |
| Primary Completion | 2024-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-08-27 with a primary completion date of 2024-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the present study is to report the cancer risk in secreting adrenal lesions. Secondary aims: to compare the incidence of cancer in secreting versus non-secreting adrenal lesions, in order to evaluate whether adrenal hormone activity can be considered an independent predictive indicator of malignancy; compare intraoperative and 30-day postoperative outcomes of patients undergoing adrenalectomy for secreting adrenal lesions versus non-secretoring lesions; regardless of the type of adrenal lesion, identify if there is one MIS adrenal approach that is superior to the others in terms of intra- and postoperative outcomes.
Eligibility Criteria
Inclusion Criteria: * Patients undergoing elective adrenalectomy; * Patients aged ≥ 18 years * Acceptance of informed consent Exclusion Criteria: Patients undergoing emergency adrenalectomy; * Patients aged ≤ 18 years * Pregnant patients
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06520111 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Adrenal Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06520111 currently recruiting?
Yes, NCT06520111 is actively recruiting participants. Contact the research team at diletta.corallino1989@gmail.com for enrollment information.
Where is the NCT06520111 trial being conducted?
This trial is being conducted at Peschiera del Garda, Italy.
Who is sponsoring the NCT06520111 clinical trial?
NCT06520111 is sponsored by University of Roma La Sapienza. The trial plans to enroll 300 participants.